South Korea: Standigm, a workflow artificial intelligence (AI) drug discovery company, has secured a US$10m investment from Pavilion Capital, a Singapore-based investment institution. The investment will be used for the clinical research of AI-driven drug compounds. Pavilion Capital focuses on private equity, venture capital funds and direct investments in companies of the North Asia and…

You must be a HMI Subscriber to view this content.

Subscribe Now »

RELATED ARTICLESMORE FROM AUTHOR